Jorga K M, Fotteler B, Modi M, Rabbia M
Department of Research and Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Eur Neurol. 2000;44(2):94-103. doi: 10.1159/000008204.
To determine the changes in haemodynamics, tolerability and pharmacokinetics that may occur when a combination of tolcapone and levodopa/carbidopa are given with desipramine.
In a crossover study, 22 healthy subjects received desipramine during two 13-day treatment periods (25 mg t.i.d. for 3 days and 50 mg t.i.d. for 10 days), with a washout period of 10-15 days. Subjects received levodopa/carbidopa (100 mg/25 mg t.i.d. for 5 days, days 9-13) and concomitant, double-blind, randomized treatment with either tolcapone (200 mg t.i.d.) or placebo.
No significant pharmacodynamic and pharmacokinetic interactions occurred between tolcapone and desipramine. Adverse events were predictable based on the known effects of the individual drugs.
Tolcapone can be combined with levodopa/carbidopa and desipramine in patients with Parkinson's disease.
确定托卡朋与左旋多巴/卡比多巴联合去甲丙咪嗪给药时可能发生的血流动力学、耐受性和药代动力学变化。
在一项交叉研究中，22名健康受试者在两个13天的治疗期内接受去甲丙咪嗪治疗（第1 - 3天，25 mg，每日三次；第4 - 13天，50 mg，每日三次），洗脱期为10 - 15天。受试者接受左旋多巴/卡比多巴（第9 - 13天，100 mg/25 mg，每日三次，共5天），并同时接受托卡朋（200 mg，每日三次）或安慰剂的双盲随机治疗。
托卡朋与去甲丙咪嗪之间未发生显著的药效学和药代动力学相互作用。不良事件可根据各药物已知的作用预测。
帕金森病患者中，托卡朋可与左旋多巴/卡比多巴及去甲丙咪嗪联合使用。
